Wanrong Xia – Trademark Portfolio

Entity Type: 01

Wanrong Xia holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 15 (Musical Instruments) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include RBNN, LIPMO, OPITY, TROIL, and FIUMNC. The owner is based in Hunan.

Cunmin 4th Group, Shuanglong Village,

Hekou Town, Linli County,

Hunan 415200 , CN

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

GGWNLY
GGWNLY
Registered 2020
TROIL
TROIL
Registered 2020
FIUMNC
FIUMNC
Registered 2020
OPITY
OPITY
Registered 2020
RBNN
RBNN
Registered 2020
LIPMO
LIPMO
Registered 2020

Trademark Classifications

Wanrong Xia's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

15
Musical Instruments (3 filings)

Musical instruments

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Wanrong Xia have?

Wanrong Xia has 6 U.S. trademarks filed with the USPTO. Of these, 6 registered.

What trademark classes does Wanrong Xia file in?

Wanrong Xia files trademarks across 2 Nice Classification classes. The most active classes are Class 15 (Musical Instruments), Class 5 (Pharmaceuticals). Class 15 covers musical instruments.

What are Wanrong Xia's most well-known trademarks?

Wanrong Xia's registered trademark portfolio includes well-known marks such as RBNN, LIPMO, OPITY, TROIL, and FIUMNC. These are among 6 currently registered trademarks in the portfolio.

What is Wanrong Xia's trademark registration success rate?

Wanrong Xia has a 100% trademark registration rate, with 6 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.